Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 12;14(1):84.
doi: 10.1186/s13550-024-01146-x.

Prognostic evaluation in recurrent glioma through 11C-Choline PET/CT imaging

Geng Hu #  1 , Bin Tian #  1 , Shaoli Han  2 , Shiwei Wang  2 , Marcus Hacker  3 , Xiang Li  4   5 , Xia Bai  6
Affiliations

Prognostic evaluation in recurrent glioma through 11C-Choline PET/CT imaging

Geng Hu et al. EJNMMI Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

no conflict of interest.

Figures

Fig. 1
Fig. 1
Patient A: a 41-year-old male diagnosed with mixed oligodendroglioma (WHO grade II), underwent surgery followed by radiotherapy. 11C-choline PET/CT imaging showed increased tracer uptake in the left frontal lobe (SUVmax=2.10; SUVmean=1.22; MTV = 4.88cm3). Follow-up: Alive, survival period of 38 months Patient B: a 43-year-old male diagnosed with anaplastic oligodendroglioma (WHO grade III), underwent surgery followed by radiotherapy. 11C-choline PET/CT imaging showed increased tracer uptake in the left frontal lobe (SUVmax=5.28; SUVmean=3.17; MTV = 3.01 cm3). Follow-up: Deceased, survival period of 12 months Patient C: a 57-year-old male diagnosed with glioblastoma (WHO grade IV), underwent surgery followed by radiotherapy. 11C-choline PET/CT imaging showed increased tracer uptake in bilateral frontal lobes and the genu of corpus callosum (SUVmax=3.59; SUVmean=1.97; MTV = 24.81 cm3). Follow-up: Deceased, survival period of 6 months
Fig. 2
Fig. 2
Kaplan-Meier curves of OS according to the patients’ baseline PET-related parameters derived from tumor lesions of whole brain
See this image and copyright information in PMC

References

    1. Xu H, Zhang A, Han X, et al. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. Cancer Immunol Immunother. 2022;71(3):645–60. 10.1007/s00262-021-03022-2 - DOI - PMC - PubMed
    1. Du Q, Lin Y, Zhang W, He F, Xu Y, Chen Z. Bioinformatics analysis of LMAN1 expression, clinical characteristics, and its effects on cell proliferation and invasion in glioma. Brain Res. 2022;1789:147952. 10.1016/j.brainres.2022.147952 - DOI - PubMed
    1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20. 10.1007/s00401-016-1545-1 10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Vasilev A, Sofi R, Rahman R, Smith SJ, Teschemacher AG, Kasparov S. Using light for therapy of Glioblastoma Multiforme (GBM). Brain Sci. 2020;10(2):75. Published 2020 Jan 31. 10.3390/brainsci10020075 - DOI - PMC - PubMed
    1. Roda D, Veiga P, Melo JB, Carreira IM, Ribeiro IP. Principles in the management of Glioblastoma. Genes (Basel). 2024;15(4):501. Published 2024 Apr 17. 10.3390/genes15040501 - DOI - PMC - PubMed

LinkOut - more resources